

Provided by:



## Rheumatology Case Management 2023-2024

**Rheumatology Case Management 2023-2024 - 6/13/2023**

**June 13, 2023**

**9:00 AM - 10:00 AM**

**Online/Rheumatology Conference Room 5 White**

### **Target Audience**

This program has been designed for Internal Medicine - Rheumatology

### **Series Educational Objectives**

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss interpretation of radiology results
- 2 Discuss interpretation of advanced serologic testing
- 3 Discuss prognostic implications of rheumatologic tests
- 4 Describe how to diagnose patients earlier in disease presentation
- 5 Describe adverse effects of immunosuppressive therapy
- 6 Discuss disease progression and prognosis
- 7 Discuss immunology behind rheumatologic disease

### **Accreditation**

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### **Designation of Credit**

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**ABIM MOC:** up to 1 MOC points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**Nurses:** This activity is for 1.00 contact hours.

**Pharmacists:** This activity is not approved for pharmacy contact hours

For more information, please contact  
John Davis  
(215) 662-2792  
johdav@upenn.edu

**Check your transcript online at <https://upenn.cloud-cme.com>**

**PAs:** AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

**Approved for (PSRM) patient safety/risk management designation**

**Acknowledgement of Commercial Support\***

None

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant and, applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Anu Shahane, MD, MPH	Course Director	Nothing to disclose - 01/06/2023
Marta Bean, MD	Faculty	Nothing to disclose - 08/30/2022
Naomi Amudala, CRNP	Nurse Planner	Nothing to disclose - 09/02/2022
Joshua F. Baker, MD, MSCE	Other Planning Committee Member	Consulting Fee-Bristol-Myers Squibb (Relationship has ended)   Consulting Fee-Pfizer, Inc. (Relationship has ended) - 12/01/2022
Shubhasree Banerjee, MD	Other Planning Committee Member	Nothing to disclose - 05/11/2023
Marissa Blum, MD, MS	Other Planning Committee Member	Nothing to disclose - 11/21/2022
Ethan Craig, MD, MHS	Other Planning Committee Member	Consulting Fee-Novartis (Advanced Health Media) - 01/27/2023
Kimberly DeQuattro, MD	Other Planning Committee Member	Nothing to disclose - 02/07/2023
Chris Derk, MD, MSc	Other Planning Committee Member	Nothing to disclose - 01/06/2023
Jonathan Dunham, MD	Other Planning Committee Member	Nothing to disclose - 01/27/2023
Michael George, MD	Other Planning Committee Member	Consulting Fee-AbbVie, Inc. (Relationship has ended)   Grant or research support-Glaxo Smith Kline   Grant or research support-

		Janssen Pharmaceuticals (J&J) - 12/01/2022
Chadwick R Johr, MD	Other Planning Committee Member	Nothing to disclose - 01/27/2023
Sharon L Kolasinski, MD	Other Planning Committee Member	Nothing to disclose - 01/25/2023
Peter A Merkel, MD, MPH	Other Planning Committee Member	Consulting Fee-AbbVie, Inc.   Grant or research support-AbbVie, Inc.   Consulting Fee-Astra Zeneca Pharmaceuticals   Grant or research support-Astra Zeneca Pharmaceuticals   Consulting Fee-Boehringer-Ingelheim   Grant or research support-Boehringer-Ingelheim   Consulting Fee-Bristol-Myers Squibb   Grant or research support-Bristol-Myers Squibb   Consulting Fee-Cabaletta (Relationship has ended)   Advisor-Chemocentryx (Relationship has ended)   Grant or research support-Chemocentryx (Relationship has ended)   Consulting Fee-CSL Behring (Relationship has ended)   Consulting Fee-Dynacure (Relationship has ended)   Consulting Fee-EMD Serono (Relationship has ended)   Grant or research support-Forbuis (Relationship has ended)   Consulting Fee-Genentech (Relationship has ended)   Grant or research support-Genentech (Relationship has ended)   Grant or research support-Eicos (Relationship has ended)   Grant or research support-Electra   Consulting Fee-Sanofi Genzyme (Relationship has ended)   Grant or research support-Sanofi Genzyme (Relationship has ended)   Consulting Fee-Immagine (Relationship has ended)   Consulting Fee-Janssen Pharmaceuticals (J&J) (Relationship has ended)   Consulting Fee-Kyverna   Stocks or stock options, excluding diversified mutual funds-Kyverna   Consulting Fee-Glaxo Smith Kline   Grant or research support-Glaxo Smith Kline   Consulting Fee-Inflarx GMBH   Grant or research support-Inflarx GMBH (Relationship has ended)   Consulting Fee-Magenta (Relationship has ended)   Consulting Fee-Novartis (Advanced Health Media) (Relationship has ended)   Consulting Fee-Neutrolis (Relationship has ended)   Consulting Fee-NS Pharma   Consulting Fee-Takeda Pharmaceuticals   Grant or research support-

		Takeda Pharmaceuticals Consulting Fee-Mitsubishi (Relationship has ended)  Consulting Fee-Pfizer, Inc. (Relationship has ended)  Consulting Fee-Q32  Consulting Fee-Regeneron Pharmaceuticals, Inc. (Relationship has ended)  Consulting Fee-Sparrow  Consulting Fee-Vistara - 02/10/2023
Alexis Ogdie- Beatty, MD	Other Planning Committee Member	Consulting Fee-Pfizer, Inc.   Honoraria-Kopa/Twill, CorEvitas, Gilead  Grant or research support-AbbVie, Inc.   Grant or research support-Novartis / Amgen  Grant or research support-Pfizer, Inc.   Consulting Fee-Janssen Pharmaceuticals (J&J)  Consulting Fee-Glaxo Smith Kline  Consulting Fee-UCB  Consulting Fee-Bristol-Myers Squibb  Consulting Fee-Novartis / Amgen  Consulting Fee-AbbVie, Inc. - 09/28/2022
Rennie Rhee, MD, MSCE	Other Planning Committee Member	Nothing to disclose - 02/06/2023
Nora Sandorfi, MD	Other Planning Committee Member	Nothing to disclose - 12/15/2022
Carla Scanzello, MD	Other Planning Committee Member	Nothing to disclose - 02/06/2023
Steffan Schulz, MD	Other Planning Committee Member	Nothing to disclose - 01/27/2023
Preethi Thomas, MD	Other Planning Committee Member	Nothing to disclose - 02/10/2023

All relevant financial relationships have been mitigated.

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit where the business lines of the ineligible company relate to the content of the activity. Financial interests are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.